Please login to the form below

Not currently logged in
Email:
Password:

sunitinib

This page shows the latest sunitinib news and features for those working in and with pharma, biotech and healthcare.

Merck claims key FDA okay for Bavencio in kidney cancer

Merck claims key FDA okay for Bavencio in kidney cancer

free survival (PFS) by 5.4 months for patients with advanced RCC compared with Pfizer’s older drug Sutent (sunitinib).

Latest news

More from news
Approximately 2 fully matching, plus 64 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?

    In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients. ... In the  CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate

  • Oncology drugs under AMNOG

    Pfizer’s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines. ... Consistent with EMA market authorisations for other kidney cancer

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics